To assess in patients with CAD \[coronary artery disease\] and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation requiring ICD \[implantable cardioverter defibrillator\] intervention) within one year after randomization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
220
Pfizer Investigational Site
Aalst, Belgium
Pfizer Investigational Site
Antwerp, Belgium
Pfizer Investigational Site
Bruges, Belgium
Pfizer Investigational Site
Edegem, Belgium
To assess in patients with CAD and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia after randomisation.
Combined total mortality and major cardiovascular events.
Major cardiovascular events include acute myocardial infarction, stroke and PTCA [percutaneous coronary angioplasty] (with or without stenting) or CABG [coronary artery bypass graft] (CABG already foreseen at the moment of randomization).
Total number of appropriate ICD interventions for ventricular arrhythmias and total number of episodes of electrical storm.
An episode of electrical storm is defined as the occurrence within 24 hours of three or more ventricular arrhythmias requiring ICD intervention.
Combined total mortality, major cardiovascular events and total number of appropriate ICD interventions for ventricular arrhythmias.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Ghent, Belgium
Pfizer Investigational Site
Hasselt, Belgium
Pfizer Investigational Site
Leuven, Belgium
Pfizer Investigational Site
Athens, Greece
Pfizer Investigational Site
Crete, Greece
Pfizer Investigational Site
RIO Patra, Greece